Bristol Myers Squibb recently announced it will invest $40 billion in the U.S. over the next five years to expand its research and manufacturing presence.
“Through this investment plan, we will strengthen our presence across the country, ramp up radiopharmaceutical manufacturing, and invest in artificial intelligence and machine learning to help us significantly increase the pace of innovation,” said CEO Chris Boerner. He added that this decision will enable greater control over complex supply chains while bringing manufacturing closer to its R&D sites.
With facilities in Seattle and Bothell, Bristol Myers Squibb’s commitment to U.S.-based innovation bolsters Washington state’s life science sector, particularly in oncology, hematology and immunology.